Can a pill restore sodium balance in patients with hyponatremia?

NCT ID NCT00201994

First seen Jul 13, 2026 · Last updated Jul 14, 2026 · Updated 1 time

Summary

This phase 3 trial investigates whether the drug tolvaptan can safely and effectively correct low sodium levels in patients with hyponatremia, a condition where the body's sodium-water balance is off. The study enrolls adults with mild to moderate hyponatremia who are either euvolemic or hypervolemic (normal or excess fluid volume). Participants receive either tolvaptan tablets or a placebo, and researchers track changes in blood sodium and any clinical benefits.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Tolvaptan (also known as Samsca)
What this could lead to
If successful, tolvaptan could offer a safe, effective way to correct low sodium levels in patients with hyponatremia, potentially reducing hospital stays and complications.
What could go wrong
This is a phase 3 trial, but results may not apply to all types of hyponatremia. Tolvaptan can cause side effects like thirst, dry mouth, and, rarely, liver injury, so its use requires careful monitoring.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HYPONATREMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Universitatskilinikum Carl

    Gustav Carus, Dresden, D-01307, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.